Frontiers in Health Informatics www.healthinformaticsjournal.com
ISSN-Online: 2676-7104
2024; Vol 13: Issue 4 Open Access

Advances in the Treatment of Diabetes Mellitus

Dr. Malek Jazzan
Internal medicine specialist, Mediclinic Al Ain - Abu Dhabi -UAE
Email: dr.jazzan@gmail.com

Cite this paper as: Dr. Malek Jazzan (2024) Advances in the Treatment of Diabetes Mellitus. *Frontiers in Health Informatics, 13* (4), 688-693

Abstract
Diabetes mellitus (DM), also referred to as diabetes, is a multifaceted and enduring metabolic disorder that has become a prominent global health concern. Advances in the treatment of diabetes have evolved in recent years, offering improved management options, better outcomes, and a deeper understanding of the disease mechanisms. Metformin remains the first-line treatment for Type 2 diabetes, especially due to its ability to reduce liver glucose production and improve insulin sensitivity. Artificial intelligence (AI) is increasingly being used to personalize diabetes care. Machine learning algorithms can analyze vast amounts of patient data, including CGM readings, insulin doses, and lifestyle factors, to provide personalized recommendations and predict future glucose trends. This can significantly improve diabetes management and reduce complications. Medical nutrition therapy (MNT) is a "nutrition-based treatment provided by a registered dietitian nutritionist." It comprises nutrition diagnosis and therapeutic and professional counseling services that aid in the management of DM
Key words: DM, AI, MNT

Introduction

Diabetes mellitus, also referred to as diabetes, is a multifaceted and enduring metabolic disorder that has become a prominent global health concern. The global impact of this issue is significant, affecting a large population and presenting substantial health risks, thereby placing a considerable strain on healthcare systems. Diabetes is a medical condition characterized by elevated blood glucose levels resulting from insufficient insulin production or impaired insulin function. This condition can lead to significant complications, affecting multiple organ systems and significantly reducing the overall quality of life for individuals affected by it. **(1)**

Diabetes mellitus, particularly Type 1 and Type 2 diabetes, continues to be a major global health challenge. Advances in the treatment of diabetes have evolved in recent years, offering improved management options, better outcomes, and a deeper understanding of the disease mechanisms. Here are some of the notable advances in the treatment of diabetes mellitus:**(2)**

Insulin Therapy Innovations

Insulin Pumps & Continuous Glucose Monitors (CGMs)

Insulin Pumps: Modern insulin pumps have become more user-friendly, offering greater precision in insulin delivery. These devices can be programmed to deliver both basal (background) and bolus (meal-related) insulin, improving blood glucose control.

Closed-Loop Systems: These systems combine insulin pumps with continuous glucose monitoring (CGM) systems to create an automatic feedback loop that adjusts insulin delivery in real-time, offering more stable glucose levels and reducing the need for manual intervention.

CGMs: Continuous glucose monitoring technology has revolutionized diabetes management, allowing patients to monitor their glucose levels continuously, leading to better glycemic control and fewer instances of hypoglycemia**.(3)**

New Insulin Formulations

Rapid-acting insulin analogs (e.g., insulin aspart, insulin lispro) and ultra-long-acting insulins (e.g., insulin degludec) have improved flexibility in meal timing and reduced the risk of hypoglycemia. Efforts to develop insulin inhalers (e.g., Afrezza) and smart insulins that adjust based on glucose levels are ongoing.**(4)**

Non-Insulin Pharmacotherapies

GLP-1 Receptor Agonists

Drugs like **liraglutide**, **semaglutide**, and **dulaglutide** have become frontline therapies, especially for Type 2 diabetes. These drugs mimic the action of the glucagon-like peptide 1 (GLP-1), which enhances insulin secretion in response to meals, suppresses glucagon release, and slows gastric emptying. They have shown significant efficacy in lowering blood sugar and also have weight loss benefits, making them a dual-purpose treatment for Type 2 diabetes and obesity.**(5)**

SGLT2 Inhibitors

Empagliflozin, **canagliflozin**, and **dapagliflozin** are sodium-glucose cotransporter 2 (SGLT2) inhibitors that lower blood glucose by promoting glucose excretion in the urine. They have also demonstrated benefits in reducing cardiovascular and renal complications, making them essential in managing diabetic patients with cardiovascular disease or chronic kidney disease.**(6)**

DPP-4 Inhibitors

Sitagliptin, **linagliptin**, and **vildagliptin** are dipeptidyl peptidase-4 inhibitors that help increase insulin secretion and decrease glucagon release. These drugs have a milder effect on blood glucose compared to GLP-1 agonists but are often used in combination therapies.**(7)**

Metformin

Metformin remains the first-line treatment for Type 2 diabetes, especially due to its ability to reduce liver glucose production and improve insulin sensitivity. It is also being investigated for additional benefits such as anti-aging effects and potential cancer prevention**.(8)**

Gene Therapy and Cell-Based Therapies

Gene Editing Technologies

CRISPR-Cas9 and other gene-editing technologies hold promise for correcting genetic mutations that cause diabetes, such as those affecting insulin production or beta-cell function. Research is still in early stages, but gene therapy may one day allow for permanent treatment of diabetes by reprogramming cells to restore normal glucose regulation**.(9)**

Beta-Cell Regeneration

Efforts are underway to stimulate **beta-cell regeneration** to restore insulin-producing cells in the pancreas. Recent studies have focused on using stem cells or reprogramming other pancreatic cells into functional beta cells. This approach could provide a long-term solution for Type 1 diabetes**.(10)**

Islet Cell Transplantation

While islet cell transplantation has been a treatment option for Type 1 diabetes, its limitations include donor shortages and immunosuppressive therapy. New techniques in islet encapsulation and stem cell-derived beta cells are improving the viability of this therapy.**(10)**

Artificial Intelligence and Digital Health Technologies

AI in Diabetes Management

Artificial intelligence (AI) is increasingly being used to personalize diabetes care. Machine learning algorithms can analyze vast amounts of patient data, including CGM readings, insulin doses, and lifestyle factors, to provide personalized recommendations and predict future glucose trends. This can significantly improve diabetes management and reduce complication**s.(11)**

Digital Diabetes Platforms

A growing number of mobile apps and digital platforms are available to help individuals track their glucose levels, food intake, exercise, and insulin usage. These apps are integrated with CGMs and insulin pumps to offer real-time data to both patients and healthcare providers, leading to more effective management strategies.**(12)**

Virtual Diabetes Care

The expansion of telemedicine and remote care options has made diabetes management more accessible. Virtual consultations, remote monitoring, and continuous feedback from healthcare professionals can support patients in managing their condition more effectively, especially in underserved or rural areas**.(13)**

Pancreatic and Gut Microbiome Research

Gut Microbiome and Diabetes

Emerging research suggests that the **gut microbiome** may play a role in the development and progression of diabetes, particularly Type 2 diabetes. Studies are exploring how manipulating the gut microbiome with probiotics, prebiotics, or fecal transplants could help improve insulin sensitivity and glucose metabolism**.(14)**

The Role of the Pancreas in Type 2 Diabetes

Researchers are investigating how inflammation in the pancreas and dysfunction of pancreatic beta cells contribute to insulin resistance and beta-cell failure in Type 2 diabetes. Understanding these mechanisms may open new therapeutic avenues for preventing or reversing Type 2 diabetes.**(15)**

Surgical Interventions

Bariatric Surgery

Bariatric surgery, particularly gastric bypass, has been shown to result in significant weight loss and, in many cases, a remission of Type 2 diabetes. The mechanisms behind this effect are still under investigation, but it is believed to involve hormonal changes that improve insulin sensitivity and pancreatic function**.(16)**

Pancreatic Islet Transplantation

For patients with severe Type 1 diabetes, islet cell transplantation is an option, though it requires lifelong immunosuppressive therapy to prevent rejection. Research is ongoing to improve the success rates and reduce the need for immunosuppressants.**(17)**

Personalized and Precision Medicine

The future of diabetes treatment is moving toward **personalized medicine**, where therapies are tailored based on genetic, environmental, and lifestyle factors. This approach is particularly important as more genetic variants associated with diabetes susceptibility are discovered, which may influence the selection of treatment plans.**(18)**

Internet Intervention for Lifestyle Modification in Diabetes

Lifestyle modification is an integral part of diabetes management. It is recommended for both patients in pre-diabetic and diabetic conditions, respectively. Reduced sedentary lifestyle, increased physical activities, and healthy diets are among the recommended lifestyle modifications. The right exercise may depend on the state of the patient. The exercise helps to bring down the plasma glucose level. For a healthy diet, it is recommended that diabetic subjects take a lot of vegetables, fruits, and whole grains; choose nonfat dairy and lean meats; and limit foods that are high in sugar and fat. Other lifestyle changes include stopping smoking and reduction in alcohol intake. The lifestyle changes are usually individualized.**(19)**

Nanotechnology and Diabetes

Nanotechnology involves the use of nanoparticles (<100 nm). These nanoparticles are developed through the manipulation of individual atoms or molecules in a substance. The application of nanotechnology in medicine is termed nanomedicine. Nanomedicine involves the combination of the knowledge of nanotechnology in the application of drugs or diagnostic molecules which generally improves their ability to target specific cells or tissues. Nanotechnology in diabetes research has played several roles in improving the outcome of diabetic management in diabetics through the deployment of novel nanotechnology-based glucose measurement and insulin delivery techniques.

Nanotechnology employs non-invasive approaches for insulin delivery and the development of a more efficacious vaccine including cell-based and gene-based therapies for T1DM. The importance of nanotechnology in diabetes includes, but is not limited to, inventive diabetes diagnosis, detection of immune cell activity and beta-cell mass, monitoring of glucose level, and non-invasive insulin delivery, etc.**(20)**

Medical Nutrition Therapy in Diabetes

Medical nutrition therapy (MNT) is a "nutrition-based treatment provided by a registered dietitian nutritionist." It comprises nutrition diagnosis and therapeutic and professional counseling services that aid in the management of DM. MNT is a critical aspect of diabetes education and management. Recommendations on MNT by international collaborative groups for diabetes management have attempted to reform and provide courses for adverse nutritional transition. For instance, MNT has been employed for the treatment of GDM because carbohydrate (CHO) is the main causative agent as a result of its impact on glycaemia. According to the Institute of Medicine, pregnant women require a minimum of 175 g CHO per day, and low-CHO diets already in use traditionally for the treatment of GDM have proven to be safe. Moreover, MNT has been reported to be critical in the management of other types of DM and as such has significantly impacted patients, especially women and newborns. **(14)**

Primarily, MNT ensures the maintenance of euglycemia via adequacy in weight gain in pregnancy and growth of fetus while avoiding ketogenesis and metabolic acidosis. Nonetheless, MNT is yet to establish the optimal diet in terms of energy content and macronutrient distribution, quality, and amount, among others, in DM. the nutritional requirements for GDM patients are the same for all pregnancy cases when their carbohydrate intake is taken into special cognizance. Currently, a low-glycemic index diet has been reported to be more favorable in the management of GDM than the traditional intervention of carbohydrates restriction even though the evidence is still restrained. Caloric restrictions are very vital in the management of overweight or obesity.**(10)**

Gene Therapy and Diabetes Mellitus

Gene therapy is a technique that involves remedying the symptoms of an ailment orchestrated by a defective gene via the incorporation of the exogenous normal gene. Its advantage is that a single treatment can be used to cure any type of disease and currently, gene therapy is opening up novel treatment options in different branches of medicine. At present, gene manipulation is not limited to the addition of a gene but also gene modulation and editing. Gene therapy can also be explained as a method of introduction of a gene or gene manipulation within a cell as a curative regimen in the treatment of disease. The objective of this approach is to remedy abnormal genes that have been implicated as the causative agent in any ailment and to successfully halt the beginning of the ailment or prevent its continuation. **(18)**

The gene therapy approach involves three major intervention methods: (i) delivery of a new gene into the body, (ii) substitution of the abnormal gene with a working gene, and (iii) disabling the malfunction genes responsible for the ailment. Gene therapy can be further classified into somatic gene therapy or germline gene therapy. While the primary target in somatic gene therapy is the somatic cells often referred to as the diseased cells, the reproductive cells are the targets in germline gene therapy. Germline therapy halts the development of the disease in subsequent generations. The application of gene therapies as trends in evolving therapeutics is due to its potential for the treatment of diverse ailments including DM, autoimmune disorders, heart diseases, and cancers among others that are difficult to manage using conventional therapies .**(13)**

T1DM is an autoimmune ailment marked by T-cell-orchestrated self-damage of the islet beta cells responsible for the secretion of insulin. Its management is problematic and complex, particularly using conventional drugs. Thus, gene therapy is partly an emerging promising therapeutic alternative in its treatment. The etiology of T1DM is multifactorial involving both environmental and genetic factors akin to any other autoimmune disease. In the recent past, researchers have favourably pointed out many genes accountable for the evolution of T1DM. Thus, alteration or grappling with these genes employing gene therapy techniques will probably foster better comprehensible management of the ailment or even cure T1DM.**(5)**

Conclusion

The treatment of diabetes mellitus is evolving rapidly due to advancements in pharmacology, technology, and surgical techniques. New classes of medications, improvements in insulin delivery methods, digital health tools, and cutting-edge research in gene therapy and microbiome management are helping to improve patient outcomes. Ongoing innovation holds the promise of making diabetes a more manageable condition and, for some, even offering a path to remission. The integration of these advances into clinical practice will continue to revolutionize the way diabetes is treated in the coming years.**(3)**

References:

1. Bellary S, Kyrou I, Brown JE, Bailey CJ. Type 2 diabetes mellitus in older adults: clinical considerations and management. Nat Rev Endocrinol. 2021;17(9):534–48.
2. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020;131:110708.
3. Horton WB, Barrett EJ. Microvascular dysfunction in diabetes mellitus and cardiometabolic disease. Endocr Rev. 2021;42(1):29–55.
4. Grässel S, Muschter D. Recent advances in the treatment of osteoarthritis. F1000Research. 2020;9.
5. Sawaf H, Thomas G, Taliercio JJ, Nakhoul G, Vachharajani TJ, Mehdi A. Therapeutic advances in diabetic nephropathy. J Clin Med. 2022;11(2):378.
6. Kong M, Xie K, Lv M, Li J, Yao J, Yan K, et al. Anti-inflammatory phytochemicals for the treatment of diabetes and its complications: Lessons learned and future promise. Biomed Pharmacother. 2021;133:110975.
7. Holl J, Kowalewski C, Zimek Z, Fiedor P, Kaminski A, Oldak T, et al. Chronic diabetic wounds and their treatment with skin substitutes. Cells. 2021;10(3):655.
8. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022;27(13):4315.
9. Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care. 2021;44(2):399–406.
10. Panza R, Cattivera V, Colella J, Baldassarre ME, Capozza M, Zagaroli L, et al. Insulin Delivery Technology for Treatment of Infants with Neonatal Diabetes Mellitus: A Systematic Review. Diabetes Ther. 2024;1–16.
11. Wu YT, Zhang CJ, Mol BW, Kawai A, Li C, Chen L, et al. Early prediction of gestational diabetes mellitus in the Chinese population via advanced machine learning. J Clin Endocrinol Metab. 2021;106(3):e1191–205.
12. Choudhury H, Pandey M, Lim YQ, Low CY, Lee CT, Marilyn TCL, et al. Silver nanoparticles: Advanced and promising technology in diabetic wound therapy. Mater Sci Eng C. 2020;112:110925.
13. Zharkikh E, Dremin V, Zherebtsov E, Dunaev A, Meglinski I. Biophotonics methods for functional monitoring of complications of diabetes mellitus. J Biophotonics. 2020;13(10):e202000203.
14. Zhang S, Ge G, Qin Y, Li W, Dong J, Mei J, et al. Recent advances in responsive hydrogels for diabetic wound healing. Mater Today Bio. 2023;18:100508.
15. Wan C, Ouyang J, Li M, Rengasamy KRR, Liu Z. Effects of green tea polyphenol extract and

epigallocatechin-3-O-gallate on diabetes mellitus and diabetic complications: Recent advances. Crit Rev Food Sci Nutr. 2024;64(17):5719–47.

16. Simos Y V, Spyrou K, Patila M, Karouta N, Stamatis H, Gournis D, et al. Trends of nanotechnology in type 2 diabetes mellitus treatment. Asian J Pharm Sci. 2021;16(1):62–76.
17. Blahova J, Martiniakova M, Babikova M, Kovacova V, Mondockova V, Omelka R. Pharmaceutical drugs and natural therapeutic products for the treatment of type 2 diabetes mellitus. Pharmaceuticals. 2021;14(8):806.
18. Siehler J, Blöchinger AK, Meier M, Lickert H. Engineering islets from stem cells for advanced therapies of diabetes. Nat Rev Drug Discov. 2021;20(12):920–40.
19. Tsoutsouki J, Wunna W, Chowdhury A, Chowdhury TA. Advances in the management of diabetes: therapies for type 2 diabetes. Postgrad Med J. 2020;96(1140):610–8.
20. Grunberger G, Sherr J, Allende M, Blevins T, Bode B, Handelsman Y, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021;27(6):505–37.